Summit Therapeutics Share Discussion Threads

[freedosh] 09/5/2018 19:42

I don’t believe that was a sale. Before anyone disagrees - yes you can roll at the same price. I used to do it a lot before the 2008 crash.

[hugus maximus] 09/5/2018 18:49

However ... of course looking at the NASDAQ figures, whose shares are 5 times our value ... that's 100,000 NASDAQ shares ... so not so dramatic in the average daily volume as here ... and there does finally seem to be some enthusiasm in the USA. EDIT - Perhaps as Luminoso suggests, Summit is just riding on Sarepta's coat tails, but the NASDAQ BB's seem to be more open to their "partner" Summit .... as if some are realising that this UK company is not "competition", but a potential earner for them.

In fact EZD is potentially a much larger earner as it's designed to work for 100% boys ... not just the 13% that Eteplirsen is aiming for. Though I suspect that Sarepta investors are so thrilled at the prospects of their new partnerships with Genetic Therapy companies who are years away from fixing DMD, that they've not looked at Ezutromid seriously as a threat to their current Exon skipping drug.

[hugus maximus] 09/5/2018 18:38

Hi jag63 & Chris ... unfortunately looks like somebody ferreting their money away.

16.29 sell at 199.7 p when bid was @ 200p and offer @ 205p 250,000 shares
16.32 sell at 199.7 p when bid was @ 200p and offer @ 205p 250,000 shares

I'm not sure whether the NASDAQ takes an AIM sell or buy into account with its share price until the end of the day? Perhaps an interesting question for a clever person? It seems that our AIM price takes the share price at end of business on the NASDAQ into account when the AIM market opens the next morning. Half a million shares will surely have quite some effect on the SP?

I think in the USA there's been a slight build in overall volume of late.

Interesting times!

[chrisatrdg] 09/5/2018 17:49

Hi HM Are they Sells or Buys which would explain the share price increase although I notice the NASDAQ is also up?

[jag63] 09/5/2018 17:48

Maybe they were earlier buys

[hugus maximus] 09/5/2018 17:33

500,000 shares sold at the end of the business in the UK. That's quite some lump.

[aim_trader] 09/5/2018 10:40

Summit Therapeutics will be presenting to investors at the Proactive One2One Healthcare Forum taking place on the evening of 17th May in London. For details and registration, please click here:

[hugus maximus] 07/5/2018 13:15

Luminoso ... now they're barking at trees: "Pre-opening NASDAQ SPRT share price up again" !

[hugus maximus] 07/5/2018 13:12

This is very good news. Summit may well have so much of the suggested criteria to gain prompt FDA approval.

[waterloo01] 07/5/2018 09:16

DMD
Because of the lack of treatment options for DMD patients, the FDA said that it may permit clinical trials on “less than usual” nonclinical testing “if justified,” and that clinical pharmacology testing “is likely not needed to support a new drug's approval.”

In addition, safety trials must include enough patients and enough drug exposure to adequately assess adverse effects. Although the guideline did not go so far as allowing approval based entirely on biomarkers for dystrophin, it acknowledged interest in dystrophin markers and said such data, together with biomarker data that “reliably reflects improvements in skeletal muscle at a biochemical, cellular, or tissue level,” may be used as surrogate endpoints to support accelerated approval, as can dystrophin-related outcomes on respiratory and cardiac muscle function.

Determining the number and duration of patient exposures needed to support approval will include assessment of the nature of DMD and other severe dystrophinopathies, but safety from at least one-year exposure will usually suffice, the FDA said. The guideline does not establish required or recommended clinical outcomes for trial designers. Instead, drug developers are encouraged to propose and develop valid and reliable outcome endpoints for patients with a wide spectrum of symptoms and disease stages.

“We appreciate the FDA for their forward thinking and scientific rigor in incorporating the learnings from the last four years into this guidance,” said Laura Hagerty, PhD, scientific program officer at the Muscular Dystrophy Association.

“The trial design recommendations provide clarity for the community and emphasize reducing patient burden during drug development. Of note is the inclusion of cardiac and respiratory endpoints, which may become important as patients are living longer and new phenotypes emerge.”

[luminoso] 04/5/2018 20:34

Flipping barking ! IMO

[hugus maximus] 04/5/2018 14:47

I have to take my hat off to Sarepta's people who have steered a blinder in the last 48 hours. They utterly defy gravity. Market cap currently $5.7 billion.

[hugus maximus] 04/5/2018 11:57

That was some prophetic email ! (see previous note .... written earlier but not posted ... then seeking-alpha news just in)



Eteplirsen has just been turned down for approval by the EU health authority.

[hugus maximus] 04/5/2018 11:55

Morning Chris ... Sarepta IMO may still stumble on EU approval for Etplirsen which will surely put the cat amongst the pigeons.

If what they were doing with their $5 Billion empire wasn't so potentially catastrophic in its wide ranging serious implication, their plan might seem to be undertaken like some surreal episode from The Last of The Summer Wine, as if Compo and Cleggy had patented some unbelievable snake oil that made them millionaires overnight? (EDIT - surely that's a little unfair and not quite so fantastical?)

[chrisatrdg] 03/5/2018 22:09

Serepta SEC schedules


Above includes new costs relating cost share with Summit
Page 27
Qtr to 31st March 2018

Utrophin (Summit collaboration cost sharing) 3,197 $1,000's

Edit: There may be further information relating to their Summit deal more to read.

[luminoso] 03/5/2018 14:17

Its the bee's knees, even. I'll get my coat.

[football] 03/5/2018 12:41

The place looks really interesting where they are having the AGM might go along just to have a nose around



Wax Chandlers Hall

[chrisatrdg] 03/5/2018 11:16

AGM RNS

The Annual General Meeting will be held at 10:00am BST on Thursday, 7 June 2018 at Wax Chandlers' Hall, 6 Gresham Street, London, EC2V 7AD. UK.



I will be going anyone else?

[waterloo01] 02/5/2018 16:21

Another new analyst note from the US covering SMMT.

Janney $SMMT - BUY
Price - $13.42 | Fair Value Estimate - $27.00
Initiate with Buy - Ezutromid's Efficacy Data Under-Appreciated To Fully Reflect Summit's Potential

[chrisatrdg] 02/5/2018 09:11

Summit tweet this morning:

The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy



Edit: This is a full blown scientific report.

[luminoso] 01/5/2018 17:29

Strengthening dollar has offset recent fall on nasdaq and prevented it being translated to AIM in the form of a few pence off our price. The inertia of the SUMM price works both ways and will only really react to quite dramatic moves in SMMT over on nasdaq, I guess.

[chrisatrdg] 30/4/2018 20:06

Further cover on Summits Phase 2 DMD Trial:

Meeting Coverage > AAN
Ezutromid Shows Potential in DMD
Phase II study indicates modulating utrophin may reduce muscle inflammation

[algernon2] 30/4/2018 18:20

"Spark Therapeutics Sells Priority Review Voucher for $110 Million"

Link courtesy From Marcus on the OXB board:

We also have one of these vouchers don't we? !

[luminoso] 27/4/2018 20:27

And if the 48 week results are even better ? Great post, Hugus.
I am beginning to allow myself to get excited again about EZT.